Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2004, for eXegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company is in the process of winding down its historical drug discovery operations following a change in the Board of Directors in December 2003. The new Board is focused on resolving liabilities and redeploying residual assets. As of May 1, 2004, the company relocated its principal executive offices from Dallas, Texas, to Rochester, New York. The company currently has only one employee, David E. Riggs, who serves as President, CEO, and CFO.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenue | $0 | $13,000 |
| Operating Expenses | $769,000 | $1,075,000 |
| Net Loss | $(739,000) | $(1,000,000) |
| Net Loss Attributable to Common Shareholders | $(962,000) | $(1,031,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.06) | $(0.07) |
| Cash and Cash Equivalents (End of Period) | $9,405,000 | $14,926,000 |
| Restricted Cash | $225,000 | $600,000 |
| Total Current Liabilities | $383,000 | $1,038,000 |
| Net Cash Used in Operating Activities | $(811,000) | $(1,236,000) |
Material Changes vs. Prior Period
- Revenue: Revenue dropped to zero in Q1 2004 compared to $13,000 in Q1 2003, as the licensing agreement with Aventis, SA was terminated.
- Operating Expenses: Total operating expenses decreased by approximately 28% to $769,000. This reduction is primarily due to the elimination of Research and Development expenses ($122,000 in 2003 vs. $0 in 2004) and expenses related to strategic redirection ($148,000 in 2003 vs. $0 in 2004).
- General and Administrative (G&A): G&A expenses decreased slightly by $36,000 (4%) to $769,000. This decrease was offset by a $102,000 increase in director and officer insurance premiums.
- Liquidity: Cash and cash equivalents decreased by $727,000 during the quarter, driven by net cash used in operating activities of $811,000, partially offset by $84,000 in proceeds from option exercises.
Outlook, Risks, and Contingencies
Guidance and Outlook: Management anticipates completing the wind-down of operations by the end of the first half of 2004. The company estimates it will use $1.2 million to $1.5 million to satisfy previous commitments of the prior Board. Subsequent to the first quarter, forecasted cash usage is approximately $100,000 to $125,000 per month, assuming no new investments or business operations. Future capital needs are uncertain, and there is no guarantee that additional financing will be available on favorable terms.
Risks and Contingencies:
- NASDAQ Delisting: The company is not in compliance with the minimum $1.00 closing bid price requirement. It has been granted an extension until July 25, 2004, to regain compliance. Failure to meet this standard will result in delisting from the NASDAQ SmallCap Market, likely adversely impacting stock liquidity and price.
- Legal Proceedings:
- Weiss Litigation: A shareholder class action and derivative suit alleges mismanagement and breach of fiduciary duties by former directors. The company cannot predict the outcome or liability.
- Labidi Proceeding: A former employee filed a federal lawsuit alleging discrimination and wrongful conversion of research materials. The company believes it has meritorious defenses.
- Lease Dispute: A dispute with the landlord of the former Dallas facility regarding approximately $173,000 in claims was settled on March 19, 2004, with a payment of $33,000 made on April 1, 2004.
Investor Verification Checklist
- Verify the company's ability to maintain the $1.00 minimum share price by July 25, 2004, to avoid NASDAQ delisting.
- Confirm the status of the "Weiss Litigation" and potential financial exposure from the shareholder class action.
- Monitor the company's cash burn rate against the projected $100,000-$125,000 monthly usage to assess runway for the wind-down period.
- Review the progress of the strategic redirection committee in identifying potential new business opportunities or asset redeployment.
- Check for any updates on the settlement of the lease dispute to ensure no further claims arise from the former Dallas facility.